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Introduction. The FSAP-Marburg I polymorphism (1704G>A), which reduces FSAP activity, is associated with late complications
of carotid stenosis in humans. Therefore, this study examines the inﬂuence of the Marburg I polymorphism and the closely linked
MarburgIIpolymorphism(1280G>C)onvariouscardiovascularoutcomesintwolargeindependentstudypopulations.Methods.
The two Marburg polymorphisms in the HABP2 gene encoding FSAP were genotyped in a large population of elderly patients
at risk for vascular disease (the PROSPER-study, n = 5804) and in a study population treated with a percutaneous coronary
intervention (the GENDER-study, n = 3104). Results. In the PROSPER study, the Marburg I polymorphism was associated with
an increased risk of clinical stroke (HR: 1.60, 95% CI: 1.13–2.28) and all-cause mortality (HR: 1.33, 95% CI: 1.04–1.71). In the
GENDER study carriers of this variant seemed at lower risk of developing restenosis (HR: 0.59, 95% CI: 0.34–1.01). The Marburg
II polymorphism showed similar but weaker results. Conclusion. The increase in stroke risk in Marburg I carriers could be due
to diﬀerential eﬀects on smooth muscle cells and on matrix metalloproteinases, thereby inﬂuencing plaque stability. The possible
protective eﬀect on restenosis could be the result of reduced activation of zymogens, which are involved in hemostasis and matrix
remodeling.
1.Introduction
Factor seven activating protease (FSAP) is a plasma serine
protease known to activate factor VII (FVII) [1]a n dp r o u r -
okinase (pro-uPA) [2]. Despite these actions, it is unclear
if endogenous FSAP has a relevant role in hemostasis. The
Marburg I (1704G>A) polymorphism in the HABP2 gene
encoding FSAP, which leads to an amino acid change in
the protease domain of this protein, may lead to a pro-
thrombotic phenotype when it is associated with reduced
activation of pro-uPA, but unchanged activation of FVII [3].
Although its possible association with venous thrombosis
remains controversial [4–6], the Marburg I variant is a risk
factor for coronary heart disease [7] and late complications2 Stroke Research and Treatment
of carotid stenosis [8]. The Marburg variant is associated
with advanced atherogenesis (a lumen narrowing of >40%)
but not with early atherogenesis (occurrence of new plaques)
[8].
Furthermore, FSAP is identiﬁed as a potent inhibitor
of smooth muscle cell proliferation and migration [9],
speciﬁcally through its ability to cleave platelet derived
growth factor-BB (PDGF-BB). The FSAP Marburg I variant,
which also has reduced proteolytic activity towards PDGF-
BB, is associated with a reduced capability to suppress
neointimaformationinananimalmodel[10].Thismightbe
another mechanism by which the Marburg I polymorphism
could play a role in carotid stenosis and many other aspects
of cardiovascular disease [11].
Therefore, we investigated the inﬂuence of this polymor-
phism on clinical stroke, coronary events, vascular mortality,
and all-cause mortality in a large population of elderly
patients at risk for vascular disease (the PROSPER study,
n = 5804) and on clinical restenosis after a percutaneous
coronaryintervention(PCI)(theGENDERstudy,n = 3104).
Although not associated with altered enzymatic activity,
we also investigated the Marburg II variant (1280G>C), a
closely linked polymorphism that leads to an amino acid
change in the protease domain of FSAP.
2. Methods
2.1. Study Design and Followup of the PROSPER Study. The
protocol of PROSPER has been described in more detail
elsewhere [12]. PROSPER is a prospective multicenter ran-
domizedplacebo-controlledtrialtoassesswhethertreatment
with pravastatin diminishes the risk of major vascular
events in elderly individuals. Between December 1997 and
May 1999, we screened and enrolled subjects in Scotland
(Glasgow), Ireland (Cork), and the Netherlands (Leiden).
Men and women aged 70–82 years were recruited if they had
preexisting vascular disease or increased risk of such disease
because of smoking, hypertension, or diabetes. A total of
5804 subjects were randomly assigned to pravastatin or
placebo.Inthisgeneticsubstudy,weevaluatedthepredeﬁned
endpoints all-cause mortality, vascular mortality, and the
secondary endpoints fatal or nonfatal coronary events and
fatal or nonfatal clinical stroke. Median followup was 3.3
(interquartile range 0.5) years and 604 (10.4%) patients died
during the study [13].
2.2. Study Design and Followup of the GENDER Study. The
present study sample has been described previously [14].
In brief, the GENetic DEterminants of Restenosis project
(GENDER) was a multicenter followup study designed to
study the association between various gene polymorphisms
and clinical restenosis. The overall inclusion period of the
GENDER study lasted from March 1999 until June 2001. A
total of 3104 patients eligible for inclusion in the GENDER
study were treated successfully for stable angina, non-
ST-elevation acute coronary syndromes or silent ischemia
by PCI in 4 of the 13 referral centers for interventional
cardiology in the Netherlands. Patients treated for acute ST
elevation myocardial infarction were excluded. Experienced
operators, using a radial or femoral approach, performed
standard angioplasty with and without stent placement.
Duringthestudy,nodrug-elutingstentswereused.Followup
lasted for at least 9 months, except when a coronary event
occurred. The primary endpoint was clinical restenosis,
deﬁned as target vessel revascularization (TVR), either by
PCI or coronary artery bypass grafting (CABG). Subjects
with asymptomatic restenosis were not included and routine
angiography was not obtained. Median followup duration
was 9.6 (interquartile range 3.9) months and 304 (9.8%)
patients underwent TVR during followup.
For both studies, all endpoints were adjudicated by
independent clinical events committees. The protocols meet
the criteria of the Declaration of Helsinki and were approved
by the Medical Ethics Committees of each participating
institution. Written informed consent was obtained from all
participating patients.
2.3. Genotyping. Blood was collected in EDTA tubes at
baseline and genomic DNA was extracted following standard
procedures. The Marburg I (1704G>A) and II (1280G>C)
polymorphisms were determined using the Sequenom Mas-
sarray genotyping platform (rs7080536 and rs11575688
resp.). A multiplex assay was designed using assay designer
software (Sequenom Inc.). As quality controls, 5–10% of the
samplesweregenotypedinduplicate;noinconsistencieswere
observed. Cluster plots were made of the signals from the
low and the high mass allele. Two independent researchers
carried out scoring. Disagreements or vaguely positioned
dots produced by Genotyper 4.0 (Sequenom Inc.) were left
out of the results.
2.4. Replication. We performed in silico replication in the
genome-wide association study on stroke from the Rot-
terdam Study [15]. Genotyping was performed using the
Illumina 550K Beadchip in 5763 study participants with
subsequent imputation to 2.5 million HapMap II SNPs.
Marburg I polymorphism was not present nor were any
proxies of the Marburg I polymorphism with r2 > 0.5.
Marburg II polymorphism was present in the imputed
dataset with an imputation quality >0.8. The association
between this SNP and incident stroke was assessed in 367
incident ischemic stroke cases.
2.5. Statistical Analysis. Allele frequencies were determined
by gene counting. The Chi-squared test was used to test
the consistency of the genotype frequencies at the SNP
locuswithHardy-Weinberg equilibrium. Hazardratios (HR)
with 95% conﬁdence intervals (CI) were calculated using a
Cox proportional hazards model. All analyses were adjusted
for sex and age. The analyses with PROSPER data were
additionally adjusted for pravastatin use and country. In
the GENDER study, polymorphisms were included in a
multivariable model containing clinical and procedural risk
factors for restenosis, such as diabetes, stenting, and total
occlusion. The replication was assessed with a logistic
regressionmodeladjustedforsexandage.TheSPSSsoftware
(version 17.0.1, SPSS Inc, Chicago, ILL) was used for all
statistical analyses.Stroke Research and Treatment 3
Table 1:BaselinecharacteristicsofthePROSPERandtheGENDER
study in patients with Marburg I genotype.
PROSPER GENDER
n = 5697 n = 2957
Continuous variates (mean, SD)
Age (years) 75.3 (3.4) 62.1 (10.7)
Body mass index (kg/m2) 26.8 (4.2) 27.0 (3.9)
Categorical variates (n,% )
Male sex 2752 (48) 2110 (71)
Current smoker 1529 (27) 730 (25)
History of diabetes 602 (11) 434 (15)
History of hypertension 3530 (62) 1189 (40)
History of myocardial infarction 764 (13) 1176 (40)
History of stable angina 1529 (27) 1977 (67)
Genotype, minor allele frequency (%)
Marburg I G/A 5 4
Marburg II G/C∗ 22
All data are presented in number (%) unless otherwise stated.
∗In PROSPER and GENDER measured in 5655 and 2959 participants,
respectively.
3. Results
3.1. The PROSPER Study. Table 1 presents the patient
characteristics and minor allele frequencies. Genotyping
success rates were 98% and 97% for the Marburg I and II
polymorphisms, respectively, and there were no signiﬁcant
deviations from Hardy-Weinberg equilibrium.
UsingaCoxproportionalhazardsmodel,whichincluded
the variables sex, age, pravastatin use, and country, a sig-
niﬁcant association was found between the Marburg I poly-
morphism and clinical stroke. Figure 1 shows that the com-
bined group of heterozygotes (n = 518) and homozygotes
(n = 17) was at increased risk for clinical stroke (HR:
1.6, 95% CI: 1.13–2.28, P = .009) when compared to the
wild type group (n = 5162). Also, all-cause mortality was
signiﬁcantly higher in patients carrying one or two copies
of this variant (HR: 1.33, 95% CI: 1.04–1.71, P = .025).
The increased mortality was mainly a result of an increase in
vascular mortality (HR: 1.37, 95% CI: 0.96–1.97, P = .082),
whereas vascular mortality was mainly determined by death
from stroke. The Marburg I polymorphism did not seem to
inﬂuence the risk for coronary events (HR: 0.98, 95% CI:
0.75–1.29). Additional adjustment for traditional risk factors
(hypertension, diabetes, smoking, and cholesterol levels) did
not change the results (HR: 1.63, 95% CI: 1.14–2.31, P =
.007).
Due to its location in the same coding sequence and its
proximity to the Marburg I polymorphism we also present
dataoftheMarburgIIpolymorphismwhichshowsigniﬁcant
eﬀects on mortality (Figure 2). The similar trends observed
for this polymorphism are probably a result of the high
linkage disequilibrium between the Marburg variants. The
linkage disequilibrium coeﬃcient was 0.79, and 62% of the
Marburg II carriers were also genotyped with the Marburg
I allele. Due to a lower allele frequency of the Marburg
Clinical restenosis
All-cause mortality
Vascular mortality
Coronary events
Stroke
00 . 511 . 522 . 5
P = .06
P = .025
P = .009
Hazard ratio (95% CI)
GENDER
PROSPER
Figure 1: Marburg I hazard ratios for vascular endpoints in
GENDER and PROSPER. The Marburg I (G534E) polymorphism
is associated with an increased risk for stroke and mortality in the
PROSPER study, whereas it tends to reduce the risk for clinical
restenosis in the GENDER study.
Clinical restenosis
All-cause mortality
Vascular mortality
Coronary events
Stroke
00 . 511 . 522 . 5
Hazard ratio (95% CI)
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Figure 2: Marburg II hazard ratios for vascular endpoints in
GENDER and PROSPER. As the Marburg II polymorphism does
not lead to altered enzymatic activity, the similar trends that
were observed for this variant are probably a result of the high
linkage disequilibrium between the Marburg variants. Despite high
conﬁdence intervals, a signiﬁcant eﬀect was observed on mortality.
II polymorphism, there were only 234 heterozygotes and 4
homozygotes with the variant allele. The large conﬁdence
intervals indeed indicate that these results are less reliable
than the Marburg I ﬁndings.
Finally, we performed an analysis comparing carriers of
both alleles of Marburg I and Marburg II with carriers of the
wild-type alleles in relation to clinical stroke. A hazard ratio
of 1.60 (95% CI: 0.87–2.94) was found for the risk of clinical
stroke for subjects carrying both variant alleles; however, this
was not signiﬁcant due to low numbers.
3.2. The GENDER Study. Table 1 presents the patient char-
acteristics and minor allele frequencies. Genotyping success
rates were 95% for both polymorphisms, and there were no
signiﬁcant deviations from Hardy-Weinberg equilibrium.
In contrast with the results from the PROSPER study,
the Marburg I polymorphism (208 heterozygotes and 5
homozygotes for the variant allele) tended to reduce the
risk for clinical restenosis in the GENDER study (Figure 1),
(HR: 0.59, 95% CI: 0.34–1.02, P = .061). The protective
eﬀect was borderline signiﬁcant. Carriers of the Marburg
II variant had a slightly and nonsigniﬁcantly reduced risk
of TVR (Figure 2). In the GENDER population, 67 patients
werecarriersofbothMarburgIandIIriskalleles,accounting4 Stroke Research and Treatment
for 63% of all Marburg II carriers (105 heterozygotes and 1
homozygote).
3.3. Replication. The Marburg II polymorphism showed an
increased risk for clinical stroke in 5763 subjects of the
Rotterdam Study. Carriers of the variant allele have a 1.4
times increased risk of clinical stroke compared to carriers
of the wild-type allele (β: 0.38, SE: 0.23, P = .05).
4. Discussion
Our data suggest that the Marburg I polymorphism, which
leadstolessFSAPactivity,increasesstrokeriskandmortality.
The Marburg I associated increase in mortality was mainly
due to an increased risk of fatal stroke. Surprisingly, carriers
of this variant seemed at lower risk of developing restenosis.
TheeﬀectoftheMarburgIIpolymorphism onclinicalstroke
was replicated in the Rotterdam Study cohort.
Although FSAP was originally identiﬁed as a potential
activator of factor VII and prourokinase (pro-uPA), its role
in hemostasis remains unclear. Endogenous FSAP, of which
intravascular levels are low, has not been clearly shown to
inﬂuence blood coagulation or ﬁbrinolysis [11]. Moreover,
the Marburg I polymorphism does not seem to inﬂuence the
risk for venous thrombosis [4, 16]. However, FSAP cleaves
PDGF-BB and has been shown to inhibit vascular smooth
muscle cell proliferation and migration in vitro [9]a n din
vivo [10]. The activity of FSAP in Marburg carriers is low
and could therefore be a risk factor for atherosclerosis and
restenosis, processes which are known to be determined by
vascular smooth muscle cell proliferation.
A possible role for FSAP in human atherosclerosis was
suggested by a study showing an association of the Marburg
I polymorphism with advanced atherogenesis in carotid
arteries [8]. Despite the low number of carriers among cases
(n = 8) and controls (n = 2), their ﬁndings suggest a
role for Marburg I in carotid plaque formation. Another
study, investigating the eﬀect of Marburg I on coronary heart
disease, found no signiﬁcant eﬀect in the whole population,
but observed an interactive eﬀect on risk between the
Marburg I variant and elevated levels of cholesterol and
triglyceride [7]. The primary endpoint in that study was a
composite of myocardial infarction and the need for a PCI.
In agreement with these studies, we also found no
association of Marburg I with myocardial infarction in the
whole population of patients taking part in the PROSPER
study, whereas we did ﬁnd a signiﬁcant association with
stroke, which is known to be related to carotid plaque
formation. The observed increase in stroke risk in Marburg
I carriers could be a consequence of hyperproliferation of
smooth muscle cells, due to a reduced proteolytic activity
of Marburg I-FSAP towards PDGF-BB. Unfortunately, we
have no measurements of carotid atherosclerosis within the
PROSPERstudyonwhichtodrawmoredeﬁniteconclusions.
The possible protective eﬀect of Marburg I on clinical
restenosis in patients treated for stable angina pectoris
is diﬃcult to explain. Despite some similarities between
atherosclerosis and restenosis, such as the involvement of
inﬂammationandsmoothmusclecellproliferation,thereare
important mechanistic diﬀerences between these processes.
In contrast with atherosclerosis, which develops partly in
response to elevated lipoprotein levels and cigarette smoke,
the restenotic process is not particularly sensitive to circu-
lating lipids and smokers even seem to have a reduced risk
for restenosis [14]. It is therefore not unlikely that a genetic
risk factor would have opposite eﬀects on stroke and clinical
restenosis after PCI.
However, as opposed to WT-FSAP, Marburg I-FSAP
w a sl e s se ﬀective in preventing neointima formation in an
animal model for restenosis [10]. Based on these ﬁndings,
the Marburg I polymorphism was expected to increase
the risk for restenosis in humans. Although the protective
eﬀect observed in the GENDER study was (borderline) not
signiﬁcant, there was a strong trend towards protection. The
contradicting results not only could relate to the subjects
(mice versus humans) or the intervention site (femoral
artery versus coronary arteries), but could also be the result
of diﬀerences in the exact location and concentration of
the Marburg I-FSAP-protein, which was locally applied in
high concentrations to injured arteries in the mouse model.
Furthermore, FSAP plays a role in many diﬀerent processes
known to be important in vascular remodeling. FSAP has
recently been shown to activate the matrix metallopro-
teinases MMP2 and MMP9 (gelatinases) [17], which are
important in matrix remodeling. Further research is needed
to elucidate the precise role of FSAP in vascular remodeling
and the pathogenesis of stroke.
The Marburg II polymorphism, also located in the pro-
tease domain of FSAP, has no known functional implications
and is not associated with altered catalytic activity.
Due to its low allele frequency (2%), the Marburg II
ﬁndings are less reliable. The similar, but much weaker,
trends that were observed for this polymorphism could be
a result of the linkage disequilibrium with the Marburg I
variant. Large conﬁdence intervals indicate that the observed
signiﬁcant association with vascular mortality, which is
slightly stronger than the eﬀect of Marburg I on vascular
mortality, probably occurred by chance.
There were 263 stroke endpoints within the PROSPER
population during the 3.3-year followup. Unfortunately, we
do not have data on the separate ischemic and hemorrhagic
strokes. In the present study, both types of stroke were
combined into one clinical endpoint. Because we know from
previous studies in elderly populations that approximately
80% of all strokes is attributable to ischemic events [18,
19], the association between the Marburg I polymorphism
and clinical stroke is probably driven by an association
between the polymorphism and ischemic stroke. If there is
no association between the polymorphism and hemorrhagic
stroke, then the association we found is an underestimation
of the true relative risk for ischemic stroke.
In conclusion, we have demonstrated that carriers of the
Marburg I polymorphism are at increased risk for clinical
stroke and stroke-related mortality. Furthermore, a strong
trend towards a reduced risk for clinical restenosis wasStroke Research and Treatment 5
observed in Marburg I carriers. As Marburg I-FSAP has
reduced proteolytic activity towards PDGF-BB, the increase
in stroke risk could be a consequence of hyperproliferation
of smooth muscle cells.
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